Delcath Systems’ (DCTH) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a report issued on Tuesday,Benzinga reports. BTIG Research currently has a $23.00 price target on the stock.

A number of other analysts also recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Delcath Systems in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Canaccord Genuity Group restated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a report on Tuesday, October 21st. HC Wainwright set a $30.00 price target on shares of Delcath Systems and gave the company a “buy” rating in a research report on Monday, October 20th. Finally, Craig Hallum reiterated a “buy” rating and issued a $20.00 price objective on shares of Delcath Systems in a research report on Tuesday, October 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems presently has an average rating of “Moderate Buy” and an average target price of $22.40.

Delcath Systems Price Performance

NASDAQ DCTH opened at $8.64 on Tuesday. Delcath Systems has a 1 year low of $8.39 and a 1 year high of $18.23. The company has a market capitalization of $302.24 million, a PE ratio of 172.80 and a beta of 0.81. The company has a fifty day moving average of $10.79 and a 200 day moving average of $12.28.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $20.56 million during the quarter, compared to analyst estimates of $23.22 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. Research analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

Large investors have recently bought and sold shares of the stock. Palisades Investment Partners LLC increased its position in shares of Delcath Systems by 1.0% during the first quarter. Palisades Investment Partners LLC now owns 171,084 shares of the company’s stock worth $2,178,000 after purchasing an additional 1,757 shares in the last quarter. USA Financial Formulas purchased a new position in Delcath Systems during the 2nd quarter worth approximately $25,000. California State Teachers Retirement System acquired a new position in Delcath Systems during the second quarter worth approximately $26,000. Principal Financial Group Inc. lifted its stake in Delcath Systems by 2.1% in the first quarter. Principal Financial Group Inc. now owns 117,620 shares of the company’s stock valued at $1,497,000 after buying an additional 2,437 shares during the last quarter. Finally, Tower Research Capital LLC TRC purchased a new stake in Delcath Systems in the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.